Livial

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Livial

Quick Facts

Property Description
Active Ingredient Tibolone
Form Tablet
Pharmacological Class Selective Tissue Estrogenic Activity Regulator (STEAR)
Origin Synthetic steroid
Target Audience Postmenopausal women

What Type of Medicine is Livial (Tibolone)?

Livial is the primary trade name for the medicinal entity Tibolone, which is a unique synthetic steroid used as a specialized form of Hormone Replacement Therapy (HRT). It is a prescription-only medicine (POM) with global distribution, having been introduced to address needs distinct from conventional combined therapies. Pharmacologically, Tibolone is classified as a Selective Tissue Estrogenic Activity Regulator (STEAR). This classification is based on its ability to regulate hormone activity differently across various tissues in the body. The fundamental difference lies in its targeted, non-uniform tissue effect.

Composition and Physical Form of Tibolone

The sole active ingredient in the medicine is Tibolone, which is provided for oral administration in the established form of a tablet. This product is a single-ingredient product, which is a key differentiating factor from combined treatments that administer multiple hormones separately. Following its rapid absorption, the parent compound is quickly metabolized into three key active forms: 3α-hydroxytibolone, 3β-hydroxytibolone, and the Δ4-isomer. Tibolone generates estrogenic, progestogenic, and androgenic activities from a single administered substance.

General Role and Primary Benefit in Postmenopause

The general role of Tibolone is to address the physiological consequences associated with the significant reduction of sex hormones in postmenopausal women, typically those experiencing symptoms one year or more after their final menstrual period. By utilizing its tissue-selective effect, the medication is designed to provide targeted hormonal support. Its primary benefit is providing relief from generalized menopausal symptoms, such as vasomotor discomfort, while simultaneously supporting the prevention of bone loss. The overarching purpose is the maintenance of a more balanced hormonal influence across key biological systems for this specific patient group.

What side effects are possible with Livial?

Possible Side Effects and Safety Information

The safety profile of Livial (Tibolone) is documented in official government regulatory sources and includes both common, expected adverse reactions and serious systemic risks. Safety data are often categorized by frequency and the body system affected (System-Organ Class or SOC).


Documented Adverse Reactions

Official regulatory documents classify adverse effects by frequency:

Frequency Category Documented Side Effects (Examples)
Common (1 in 100 to 1 in 10) Vaginal bleeding/spotting, Breast tenderness/pain, Lower abdominal pain, Weight gain, Hirsutism (unusual hair growth).
Uncommon (less than 1 in 100) Acne, Genital pruritus (itching).
Rare/Very Rare Jaundice or clinically apparent liver injury, Hypersensitivity reactions.

Serious Risks and Safety Limitations

Official prescribing information highlights specific serious adverse reactions and safety limitations:

  • Vascular Risks: There is an increased risk of Venous Thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), particularly during the first year of treatment. The risk of stroke is also documented, increasing with the duration of use, especially in women over approximately 60 years of age.
  • Cancer Risks: The safety data show an increased risk of certain cancers, including endometrial cancer and breast cancer, which generally increases with the duration of use.
  • Contraindications: Use is restricted (contraindicated) in individuals with specific pre-existing conditions, such as a history of VTE or arterial thromboembolic disease, known or suspected breast or endometrial cancer, undiagnosed genital bleeding, and active liver disease. These restrictions define the absolute safety boundaries for the medicine's use.

Exposure- and Age-Related Safety Patterns

The risks of stroke and certain cancers are explicitly tied to the duration of use. Furthermore, regulatory guidance notes that the absolute risk of adverse effects may be lower, and the benefit-risk balance more favourable, for women with premature menopause compared to older women.

Overdose and Emergency Response

The official regulatory documentation for Livial (tibolone) defines its acute overdose profile as having a low toxicity, meaning that the occurrence of severe or life-threatening toxic effects is not expected. This classification is supported by regulatory studies indicating that acute toxic effects are unlikely to occur, even when the doses taken significantly exceed the prescribed amount.

The officially documented clinical signs of an acute overdose are limited to two primary expected manifestations. These may include the onset of gastrointestinal disturbance or discomfort, and the occurrence of vaginal bleeding. These effects are typically self-limiting, reflecting the drug’s hormonal activity and the overall low acute toxicity profile.

Required Emergency Actions

Regulatory authorities universally mandate that immediate medical attention must be sought in all cases of suspected overdose. This directive applies even when the individual exhibits no immediate signs of discomfort or other poisoning symptoms. Contacting a doctor or emergency services immediately is the required action whenever an overdose is suspected.

In the absence of a known, specific pharmacological antidote, the mandated approach to care described in the official prescribing information is symptomatic and supportive treatment. This management strategy focuses on addressing any clinical manifestations that may present.

Therapeutic Uses of Livial

What Livial Treats: Main Uses and Benefits

Livial (tibolone) is primarily used to address symptoms that occur after menopause and to provide supportive relief for bone health. Its two main therapeutic uses are addressing symptoms related to systemic imbalance and providing supportive relief for conditions where functional stability becomes affected.

Licensed indications cover the treatment of symptoms related to systemic imbalance and supportive therapy for conditions presenting with disruptive symptom manifestations.


Symptom Management and Supportive Relief

Livial is commonly used when short-term symptomatic assistance is needed, such as during phases where symptoms become more noticeable. It helps address symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort (hot flushes and sweating), symptoms linked to organ-specific functional stress (dryness and irritation), and certain symptoms associated with acute or episodic changes (low mood and irritability).

The intent is generally to provide support that helps ease the overall symptom burden, assisting with maintaining functional stability. The therapy is considered relevant when supportive symptom management is appropriate to help improve day-to-day comfort during symptomatic periods.


Quick Fact: Support for Symptoms related to Physical Discomfort Livial is applied across domains where additional symptomatic support is needed to help manage episodes of sudden heat and sweating that can interfere with daily functioning.

Regulatory References

  1. GOV.UK (MHRA) guidance

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Livial (tibolone) is officially indicated for use exclusively in postmenopausal women, generally those who are more than one year past their last natural menstrual period. Use in women who are less than 12 months post-menopause is typically not recommended due to a higher risk of irregular bleeding.

The medicine is strictly contraindicated and must not be used by individuals with certain pre-existing conditions, as defined in regulatory documentation. Absolute exclusions include any current or past history of hormone-sensitive cancers (such as breast or endometrial cancer) or any suspicion of these conditions.

Contraindications also apply to individuals with a history of or current thromboembolic disease, including blood clots in the veins (like Deep Vein Thrombosis or Pulmonary Embolism) or arteries (like stroke or heart attack). Furthermore, patients with acute or uncontrolled liver disease (where liver function tests are not normal), undiagnosed genital bleeding, or untreated endometrial hyperplasia are ineligible for treatment. Use is also formally prohibited during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Livial (tibolone) can interact with certain other medicinal products, leading to changes in the effects of either Livial or the co-administered medicine. These interactions are primarily related to how the body processes the medication.

Key Interaction Categories

Category Specific Medicines/Products Effect & Caution
Anticoagulants Coumarin derivatives, such as warfarin Livial may enhance the anticoagulant effect, potentially increasing the risk of bleeding. Close monitoring of blood clotting parameters, such as the INR, is essential.
Enzyme Inducers Medicines for epilepsy (e.g., phenytoin, carbamazepine) and tuberculosis (e.g., rifampicin). These substances increase the metabolism (breakdown) of tibolone in the liver, which can decrease the therapeutic effect of Livial.
Herbal Remedies St John's Wort (Hypericum perforatum) This herbal product is a known enzyme inducer and may similarly accelerate tibolone's metabolism, reducing its clinical effectiveness.

Important Considerations

Before starting Livial, inform your healthcare provider about all medicines, over-the-counter products, and herbal supplements you are taking. Caution and dose adjustment may be required if combining Livial with any substance that affects liver drug-metabolising enzymes or blood coagulation.

Mechanism of Action

How Livial Works

Livial's mechanism of action is based on the highly targeted activity of its three primary metabolites, which defines its classification as a Selective Tissue Estrogenic Activity Regulator (STEAR). The mechanism involves the coordinated engagement of multiple steroid receptors and key metabolic enzymes across different tissues.


Multi-Receptor Agonism for Systemic Influence

The metabolites of Tibolone simultaneously engage Estrogen Receptors ( ER), Progesterone Receptors (PR), and Androgen Receptors (AR). The estrogenic activity in the Central Nervous System (CNS) mediates the stability of the hypothalamic thermoregulatory center, while ER agonism in bone tissue reduces osteoclast function, resulting in the maintenance of bone mineral content.


Localized Enzyme Modulation for Tissue Selectivity

The unique profile is maintained by manipulating local steroid metabolism. In the endometrium and breast, the drug's metabolites inhibit the Steroid Sulfatase (STS) enzyme and stimulate Steroid Sulfotransferase (SULT). This enzymatic shift promotes the local conversion of potent active estrogens into inactive sulfate conjugates, which modulates estrogenic signaling to minimize proliferative activity in these tissues.

Dosage and Administration Information

Administration Guidelines for Livial

Livial (tibolone) is a medicine for oral use only, administered as a single 2.5 mg tablet per day. The regimen is typically standardized and continuous, focused on using the lowest effective dose for the shortest possible duration to manage the condition.

Administration Schedule and Timing

The standard dosage is one 2.5 mg tablet taken once daily without interruption, following a continuous schedule. The tablet is swallowed whole with water or another drink, preferably at the same time every day. The intake is independent of meals and can be taken before or after food.

For women experiencing natural menopause, treatment is initiated at least 12 months after their final natural menstrual bleed. If switching from a sequential hormone therapy, administration starts the day following the completion of the prior regimen.

Handling of Missed Doses

If a dose is missed, standard protocol involves a 12-hour grace period. The missed tablet is taken immediately only if it is remembered within 12 hours of the usual time. If more than 12 hours have elapsed, the missed dose is skipped entirely, and the next dose is taken at the normal scheduled time. A separate progestogen is not added to the tibolone regimen.

Recent Clinical Evidence

Livial: Recent Clinical Evidence

Recent clinical research on Livial (tibolone) has focused on evaluating its effectiveness for menopausal symptoms and its specific safety profile across various body tissues compared to conventional Hormone Therapy (HT) and placebo.


Efficacy in Menopausal Symptoms and Bone Health

  • Vasomotor Symptoms: Studies comparing tibolone to placebo suggest that tibolone is associated with a greater reduction in the frequency of vasomotor symptoms, such as hot flashes and sweating. However, when compared to combined conventional HT, some evidence suggests combined HT may be associated with a greater reduction in these symptoms.
  • Sexual Function and Mood: Research has specifically investigated tibolone's potential positive influence on sexual well-being, mood, and libido, suggesting an association that may be related to its unique pharmacological properties.
  • Bone Mineral Density (BMD): Clinical trials indicate that tibolone is associated with maintaining or increasing BMD in postmenopausal women, reducing bone loss in the lumbar spine and femoral neck compared to non-active controls. Evidence suggests this effect may be comparable to the effect observed with estrogen therapy.

Safety and Side-Effect Profile

The safety profile of tibolone has been a major focus of large-scale studies:

  • Unscheduled Bleeding: Tibolone is associated with a higher rate of unscheduled vaginal bleeding compared to placebo, but it is associated with a lower rate of bleeding compared to combined conventional HT.
  • Endometrial Safety: Studies examining the lining of the uterus (endometrium) generally report that tibolone does not induce endometrial hyperplasia or carcinoma, a key concern with unopposed estrogen use.
  • Serious Adverse Events: Long-term data from some studies have raised safety concerns in specific patient groups, including an observed increased risk of stroke in women over 60 years of age and an increased risk of breast cancer recurrence in women with a prior history of breast cancer. The overall risk profile must be carefully evaluated by a healthcare professional.

Key Studies & References

  1. Tibolone: benefit-risk balance (UK Government Drug Safety Update, discussing LIFT and LIBERATE)

Frequently Asked Questions (FAQ)

Common questions about Livial (FAQ)

Q: How quickly should I expect to feel better after starting Livial?

Regulatory information suggests that some relief from symptoms like hot flushes and sweating may start within a few weeks of beginning treatment. The full therapeutic effect, if achieved, is often noted after two to three months of continuous use.

Q: Can Livial help with changes in mood during menopause?

Studies and official information indicate that Livial is associated with a positive effect on mood and sexual well-being. It is sometimes noted for helping specifically with low mood that may be associated with the menopausal transition.

Q: Can Livial be taken at the same time as supplements like calcium or Vitamin D?

Official drug labels list specific drug interactions, such as those with blood thinners, enzyme inducers, or St John's wort, but do not specifically list common supplements like calcium or Vitamin D. It is important for patients to inform a healthcare provider about all the supplements they are taking.

Q: Is Livial suitable for women who have had a hysterectomy?

Official prescribing information indicates that women who have had a hysterectomy (surgical removal of the uterus) are generally eligible for the medicine. They may start treatment at any time, provided they meet all other eligibility criteria.

Q: Can women with a family history of breast cancer use Livial?

Official product information focuses on a patient's personal history of hormone-sensitive cancers as a contraindication. A family history alone is not listed as an absolute restriction, but a healthcare provider must determine the appropriate benefit-risk balance.

Q: What's the typical duration of treatment with Livial?

Clinical guidance suggests that Livial is commonly used for 2 to 5 years to manage menopausal symptoms. The treatment duration is continuously reviewed by a healthcare professional to ensure the use of the lowest effective dose for the shortest necessary duration.

Q: Is it normal for my breasts to feel tender after starting Livial?

Official safety information reports that breast tenderness or pain is a common side effect associated with the medicine. This is typically a temporary effect and often improves or resolves after the initial few weeks as the body adjusts to the medication.

Q: Does alcohol consumption affect the effectiveness of Livial?

Regulatory documents do not list alcohol as a substance that directly affects the core effectiveness or metabolism of Livial. However, general health advice may still recommend reducing alcohol intake to help manage hot flushes.

Q: Does taking Livial affect mammogram results?

Studies on Livial (tibolone) suggest that it does not typically increase breast density, which is a possible concern with some hormone therapies. The need for regular mammograms and breast examinations should be discussed with a healthcare provider while using this medication.

Q: What are the expected benefits of taking Livial for menopause symptoms?

Official information states that the medicine is indicated for relief from symptoms such as hot flushes and sweats and to help prevent bone loss (osteoporosis). Clinical use also reports benefit for local symptoms like vaginal dryness and potentially low mood.

Q: How does Livial compare to traditional estrogen-only HRT?

Clinical guidance notes that Livial demonstrates similar efficacy to standard postmenopausal hormone regimens for relieving symptoms such as hot flushes and vaginal dryness. It may be noted for its distinct effect on sexual well-being.

Q: Can Livial affect hair growth or loss?

Official safety documents list hirsutism (unusual hair growth) as a common side effect. Less commonly, loss of scalp hair (alopecia) has also been reported in clinical experience.

Q: Is Livial a good option for managing vaginal dryness?

Due to its estrogenic effect on vaginal tissue, Livial is frequently reported in clinical guidance to provide benefit in relieving symptoms of vaginal dryness and associated discomfort.

Q: How does Livial influence libido?

Studies and clinical experience have noted an association between Livial and a positive influence on libido and sexual function in some postmenopausal women. This is thought to be related to its specific mechanism of action.

Q: Can taking Livial affect my cholesterol levels?

Official product information indicates that Livial has been associated with a decrease in HDL cholesterol, sometimes referred to as the 'good' cholesterol. No significant changes are typically observed in the other major cholesterol types.

Q: Is the dose of Livial the same for everyone?

The regimen for Livial is highly standardized, with one tablet taken once daily. A healthcare provider determines the appropriateness of this standard dose for each patient, based on their clinical needs.

Q: Can Livial be used for perimenopausal symptoms?

Official prescribing information specifies that Livial is indicated only for postmenopausal women. Use is generally restricted to those who are at least 12 months past their final menstrual bleed to minimize the risk of irregular bleeding.

Q: Can I take Livial if I have migraines?

The potential for severe or migraine-type headaches is listed as a rare serious adverse effect. The presence of pre-existing conditions, such as a history of migraines, is assessed by a healthcare provider when considering treatment.

Q: Do I need regular check-ups while taking Livial?

Official guidance indicates that regular medical check-ups are part of the standard management for patients using hormone therapies. These often include monitoring of breast health and general health evaluations.

Q: What is the active metabolite of Livial?

The parent compound, tibolone, is metabolized into three key active forms: 3alpha-hydroxytibolone, 3beta-hydroxytibolone, and the Delta4-isomer. These active forms contribute to the medicine's overall effect.

How should Livial be stored and disposed of?

The official product labeling for Livial (tibolone) specifies strict conditions to maintain tablet stability and ensure safety.

Storage Conditions

Livial must be stored at a temperature not exceeding 25 C. The tablets must be protected from light and moisture and should remain in the original packaging (blister strip within the outer carton) until they are taken. The product must always be stored in a safe place, out of the sight and reach of children.

Disposal Instructions

Expired or unused Livial should not be disposed of via household waste or wastewater. According to regulatory guidelines, any unused medicinal product must be disposed of in accordance with local requirements for pharmaceutical waste, often through a pharmacy take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Livial found in:

A-Z Index: